Discusses Year-End Late-Stage Pipeline Review With Focus on Clinical and Regulatory Developments December 16, 2025 11:15 AM ...

The PERSEUS trial was a global, double-blind, randomized Phase 3 study comparing tolebrutinib to placebo in PPMS patients.

Sanofi will not be pursuing approval of tolebrutinib for PPMS, and an FDA decision on the therapy in nonrelapsing SPMS will ...

Kyverna Therapeutics announced positive topline data from a phase II trial of mivocabtagene autoleucel, a chimeric antigen ...

Sanofi has agreed $1.7bn and $1.04bn licensing deals with Dren Bio and ADEL, respectively. Following the disappointment of a ...

Tolebrutinib failed to meet the primary endpoint in the phase 3 PERSEUS study involving patients with primary progressive multiple sclerosis.

Shares of Sanofi SNY fell nearly 2% on Monday after the company reported two setbacks in connection with its investigational ...

The ECB meets on Thursday and is widely expected to hold its key rate at 2% for a fourth straight meeting. Traders will be ...

Find insight on Hygeia Healthcare, Sanofi, Hikma Pharmaceuticals and more in the latest Market Talks covering Health Care.

The FDA has delayed tolebrutinib’s review date again, as Sanofi also posted a Phase III failure for the MS candidate.